Dimensional Fund Advisors LP Otonomy, Inc. Transaction History

Dimensional Fund Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.25 - $2.24 $126,844 - $1.14 Million	-507,377 Reduced 57.05%	381,902 $112,000
Q2 2022 Aug 12, 2022	BUY	$1.72 - $2.51 $81,846 - $119,438	47,585 Added 5.65%	889,279 $1.85 Million
Q1 2022 May 13, 2022	BUY	$1.72 - $2.47 $218,004 - $313,065	126,747 Added 17.73%	841,694 $2.02 Million
Q4 2021 Feb 09, 2022	SELL	$1.69 - $2.31 $75,590 - $103,321	-44,728 Reduced 5.89%	714,947 $1.49 Million
Q3 2021 Nov 12, 2021	SELL	$1.22 - $2.2 $516,549 - $931,482	-423,401 Reduced 35.79%	759,675 $1.46 Million
Q2 2021 Aug 12, 2021	SELL	$2.06 - $2.67 $54,468 - $70,597	-26,441 Reduced 2.19%	1,183,076 $2.64 Million
Q1 2021 May 14, 2021	BUY	$2.49 - $6.23 $88,372 - $221,108	35,491 Added 3.02%	1,209,517 $3.08 Million
Q4 2020 Feb 25, 2021	BUY	$3.48 - $6.47 $4.09 Million - $7.6 Million	1,174,026 New	1,174,026 $7.6 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.